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Abstract
Glutathione (GSH) is the most abundant cellular thiol playing an essential role in preserving a reduced cellular environment.
Cellular GSH levels can be efficiently reduced by the GSH biosynthesis inhibitor, L-buthionine sulfoximine (BSO). The aim of
our study was to determine the role of GSH in the growth of two C-cluster enteroviruses, poliovirus type 1 (PV1) and
coxsackievirus A20 (CAV20). Our results show that the growth of both PV1 and CAV20 is strongly inhibited by BSO and can
be partially reversed by the addition of GSH. BSO has no effect on viral protein synthesis or RNA replication but it strikingly
reduces the accumulation of 14S pentamers in infected cells. GSH-pull down assays show that GSH directly interacts with
capsid precursors and mature virus made in the absence of BSO whereas capsid precursors produced under GSH-depletion
do not bind to GSH. In particular, the loss of binding of GSH may debilitate the stability of 14S pentamers, resulting in their
failure to assemble into mature virus. Immunofluorescence cell imaging demonstrated that GSH-depletion did not affect the
localization of viral capsid proteins to the replication complex. PV1 BSO resistant (BSOr) mutants evolved readily during
passaging of the virus in the presence of BSO. Structural analyses revealed that the BSOr mutations, mapping to VP1 and
VP3 capsid proteins, are primarily located at protomer/protomer interfaces. BSOr mutations might, in place of GSH, aid the
stability of 14S particles that is required for virion maturation. Our observation that BSOr mutants are more heat resistant
and need less GSH than wt virus to be protected from heat inactivation suggests that they possess a more stable capsid. We
propose that the role of GSH during enterovirus morphogenesis is to stabilize capsid structures by direct interaction with
capsid proteins both during and after the formation of mature virus particles.
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Introduction
Glutathione (GSH), c-L-glutamyl-L-cysteinylglycine, is an
important cellular reducing agent, which prevents damage to
cellular components caused by free radicals or peroxides. In
addition, GSH has roles in signal transduction, gene expression
and apoptosis [1]. The thiol group (SH) of GSH’s cysteine serves
as a proton donor and is responsible for the biological activity of
GSH. Glutathione is present in several forms in cells, tissues, and
plasma, at a high concentration of about 5 mM. It primarily exists
in free form either in a reduced (GSH) or in an oxidized state
(GSSG). GSH is also capable of forming disulfide bonds with
cysteine residues in proteins and in its bound form it regulates
protein function [1].
The cellular synthesis of GSH takes place in two consecutive
steps. The first and rate-limiting step is the synthesis of a
dipeptide, catalyzed by c-glutamylcysteine synthase. In the
second step glycine is added to the dipeptide in a reaction
catalyzed by glutathione synthase. L-buthionine sulfoximine
(BSO) is a specific and selective inhibitor of c-glutamylcysteine
synthase and consequently of GSH synthesis [2]. Pretreatment of
HeLa cell monolayers with BSO reduces the total GSH level to
,1% of control values by 48 hr post treatment [3]. Previous
studies with BSO have shown that GSH influences viral
replication. Specifically, BSO pretreatment of cells enhanced
the replication of HIV, influenza virus, HSV-1 and Sendai virus
[4–7]. In contrast, recently it was shown that BSO inhibits
replication of coxsackievirus B3(CVB3), a B-cluster enterovirus,
by blocking virus morphogenesis [3]. Early studies with PV have
shown that in the presence of 5–10 mM glutathione the eclipse
period of poliovirus infection is blocked [8]. Eclipse refers to an
early phase of the viral replication cycle during which the
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subsequent production of progeny virions. Adsorption and
penetration of the virus to the host cell were not affected but
the entering particles were not uncoated. Studies on the effect of
BSO on Echovirus 9 proliferation indicated that the drug
inhibited apoptosis induced by this virus [9]. Finally, GSH was
found to stabilize purified poliovirus (PV) particles to in vitro heat
inactivation, similarly to the action of S7, methylthiopyrimidine
[10] or arildone, an antiviral agent that reversibly blocks the
uncoating of PV [11].
Poliovirus (PV) is a plus strand RNA virus in the Enterovirus
genus of the Picornaviridae. The 7.5 kb genome of poliovirus
contains a single open reading frame, which encodes one capsid
(P1) and two nonstructural domains (P2 and P3) (Figure 1). The P1
precursor, after interacting with cellular chaperone Hsp90 [12]
adopts a processing-competent conformation that is cleaved by
viral proteinase 3CD
pro [13] into capsid proteins VP0, VP1 and
VP3 (Table 1). These assemble to form a 5S protomer and then
five protomers assemble yielding a 14S pentamer. Twelve
pentamers make up the 75S empty viral capsid. The viral particle
containing RNA, the provirion (150S), undergoes the final
maturation cleavage of VP0 to yield VP2 and VP4. Whether the
progeny RNA is inserted into the empty capsid or the pentamers
surround and enclose the viral RNA remains an unanswered
question. The experimental evidence available thus far favors the
idea that 14S subunits are key assembly intermediates in PV1
morphogenesis. Studies using the in vitro cell-free translation/
replication system demonstrated that 14S particles interact with
newly made viral RNA and are assembled into virions [14]. In
addition, electron microscopic analyses indicated that 14S
particles associate with the replication complex and can be
cross-linked to viral RNA by UV-irradiation [15]. Finally, Nugent
and Kirkegaard observed that only 14S particles and mature
virions interacted in vitro with poliovirus RNA but empty capsids
did not [16]. The question of whether 75S empty capsids are the
storage form of pentamers or dead-end products is still contro-
versial [14,17–20].
Although the basic steps involved in the encapsidation of
poliovirus RNA are well established, very little is known about
details of the overall process. We have recently made the interesting
observation that the specificity of enterovirus encapsidation (PV,
C-CAV) is determined by an interaction between capsid proteins
and nonstructural protein 2C
ATPase [21]. An alanine scanning
mutagenesis analysisof the 2C
ATPase polypeptide strongly supported
this model and identified, in addition, a domain near the C-
terminus that is required for morphogenesis. Indeed, mutations in
VP1 and VP3 were found to compensate for the defect in
encapsidation [22]. Our recent work led us to conclude that no
RNA encapsidation signal is involved in poliovirus assembly
[21,22].
As part of our ongoing studies on the morphogenesis of C-
cluster enteroviruses, we have examined the effect of GSH on
encapsidation by using drug inhibition and biochemical experi-
ments. In this study we observed that BSO blocked the production
of both PV1 and CAV20 in tissue culture cells by more than
hundred fold. Neither protein synthesis nor RNA replication were
affected by the drug treatment. However, we observed that the
level of 14S pentamers was severely reduced in the absence of
GSH due to BSO-treatment. Consequently very little, if any,
infectious mature virus was produced. Immunofluorescence cell
imaging confirmed the absence of mature virus in drug-treated
PV1-infected lysates even though capsid proteins colocalized with
nonstructural proteins in the replication complex. GSH-pull down
assays indicated that GSH physically interacts with the mature
virus and capsid precursors. Drug resistant mutations map to
capsid proteins VP1 and VP3. Structural analyses of capsids of
BSO-resistant mutants indicate that the mutations are located at
protomer/protomer interfaces of pentamers supporting a role for
GSH in the stabilization of these precursors. Heat-inactivation
studies confirm the proposed stabilizing effect of GSH on purified
PV1 particles. Our results suggest that the effect of GSH on PV
morphogenesis is specific and that the primary function of GSH is
to stabilize the capsid proteins both during and after their
assembly into the viral particle.
Results
BSO inhibits the growth of both PV1 and CAV20 on HeLa
cells
In view of the relatively high cellular concentration of GSH
(5 mM), HeLa cells have to be pretreated with BSO (0.4 mM) for
48 hr to reduce its concentration to below detectable levels [3].
We used these conditions to test the effect of BSO-pretreatment on
poliovirus infection. In preliminary experiments untreated or
BSO-pretreated HeLa cell cultures were infected with wild-type
type 1 PV (PV1-wt) and incubated for 8 hr in the absence or
presence of the drug, respectively. A measurement of the virus titer
by plaque assays indicated a 100-fold reduction in the yield of virus
produced in the presence of the drug (Figure 2A). In a parallel
experiment a mixture of BSO resistant (BSOr) variants, isolated by
passaging PV1-wt on HeLa cells in the presence of BSO, were also
tested. The drug had no effect on the growth of the BSOr variants
(Figure 2A).
Similarly, proliferation of CAV20-wt, another member of the
C-cluster enteroviruses, was also found to be severely inhibited in
BSO-treated HeLa cells (data not shown). BSO resistant CAV20
(CAV20-BSOr) mutants were also isolated on BSO-treated cells
after several passages in the presence of 0.4 mM BSO although
these mutants did not arise as easily as the PV1-BSOr mutants
(data not shown). Together, these results suggest that GSH is
required for the growth of both PV1 and CAV20 since BSO, the
inhibitor of GSH synthesis, blocks virus production.
Author Summary
Enteroviruses are plus stranded RNA viruses in the
Picornaviridae family that cause as many as 3 billion
infections per year. Enterovirus morphogenesis, which
involves the encapsidation of newly made viral RNAs, has
been studied for many years but the process is still poorly
understood. Elucidation of this process is important for the
development of drug treatments for a variety of human
diseases. We describe the role of glutathione, an important
cellular reducing agent, in enterovirus morphogenesis by
studying the inhibition of GSH biosynthesis with BSO on
viral proliferation. We discovered that GSH directly
interacts with viral capsid precursors and the mature virus.
In the presence of BSO the accumulation of a small capsid
precusor (pentamer) is reduced and consequently no
mature viruses are produced in virus-infected cells. Drug
resistant viruses are easily isolated with mutations located
in two of the capsid proteins, VP1 and VP3. We propose a
model to explain the role of GSH in enterovirus morpho-
genesis, which is to stabilize the capsid precursors and the
mature virus during and after the encapsidation of the
progeny viral RNA by direct interaction with capsid
proteins.
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Next we tested whether the requirement for GSH during PV
growth is specific or whether GSH can be replaced by other
reducing agents, such as dithiothreitol (DTT), b-mercaptoethanol
(b-ME) or GSSG, the oxidized form of GSH (Figure 2B).
Untreated or BSO-pretreated HeLa cells were infected with
PV1-wt and at 2 hr post infection various compounds (5 mM)
were added to the cultures. Incubation continued for 8 hr in the
absence or presence of BSO, respectively (Figure 2B). Both GSH
and DTT but not GSSG, were able to reverse the inhibitory effect
of BSO, albeit only partially. Partial rescue by DTT, however,
does not necessarily mean that it can directly replace GSH-
function in poliovirus growth and morphogenesis. DTT, a
reducing agent frequently used in biochemical experiments, might
function indirectly, for example, by reducing GSSG (that by itself
does not rescue inhibition) to GSH. Surprisingly, b-ME, another
common reducing agent in the laboratory, lacked the ability to
overcome the inhibitory effect of BSO. It should be noted that in
studies with CVB3 no reversal of the BSO-induced inhibition of
viral growth was achieved by either DTT or by b-ME [3].
BSO-resistant mutations are mapped to capsid proteins
VP1 and VP3
To map the mutations in BSO resistant variants of both PV1
and CAV20, the plaque-purified viruses were subjected to full-
length genome sequence analyses. Three PV1-BSOr variants
revealed an array of mutations in capsid proteins VP1 and VP3,
whereas only a single VP3 mutation was found in 4 different
plaque-purified CAV20-BSOr mutants (Figure 3A).
H. A. Thibaut and his colleagues have recently observed that
the small compound TP219 inhibits the replication of several
enteroviruses by binding GSH (Thibaut et al. in press). Interest-
ingly, the replication of the poliovirus vaccine strain Sabin 1 was
resistant to TP219 (Thibaut et al, submitted for publication). Since
TP219 depletes available cellular GSH we have followed
Thibaut’s observation and found that, indeed, PV type 1 Sabin
virus is also resistant to depletion of GSH by BSO (Figure 3B). The
Sabin 1 vaccine strain was initially isolated following numerous
passages of its progenitor strain PV1(Mahoney) in different non-
human tissue culture cells and monkeys [23]. The passages lead to
21 amino acid changes in the viral polyprotein, of which 12 are
located in the capsid domain [24] (Figure 3A). Only 4 of the 12-
capsid mutations have been assigned to the attenuated phenotype
of the PV type 1 Sabin vaccine [23]. We do not know yet which of
the 12-capsid mutations in PV type 1 Sabin are responsible for the
BSOr phenotype.
Growth curves of PV1 and CAV20 on HeLa cells in the
presence of BSO
To examine the effect of BSO on the growth of C-cluster
enteroviruses in more detail we analyzed growth curves of wt and
of drug-resistant PV1 (VP3 Q178L) and of CAV20 (VP3 Y97H)
on HeLa cells, which were untreated (2BSO) or treated with the
drug (+BSO). HeLa cell cultures were infected at a moi of 10 with
wt or drug resistant variants of PV1 and incubation was with or
without BSO, as indicated. Virus titers were monitored by plaque
assay at various times, up to 8 hr post-infection. As shown in
Figure 3C, PV1-infected control cells yielded 10
9 PFU/ml but the
drug reduced the yield about 100 fold at 4 hr and 8 hr post
infection. In contrast, the depletion of GSH did not affect the
growth of PV1-BSOr variant (VP3 Q178L) (Figure 3C). Essen-
tially the same results were obtained with CAV20, except that
drug treatment reduced the titer of the wt virus nearly 10,000-fold
(Figure 3D). Again, the growth of CAV20-BSOr variant (VP3
Y97H) was unaffected in GSH depleted cells, and in the presence
Figure 1. Genome structure of PV1 RNA and polyprotein processing. The PV1 genomic RNA contains a 59NTR, a single open reading frame, a
39NTR and poly (A) tail. The polyprotein, translated from a single open reading frame, has one structural (P1) and two nonstructural domains (P2, P3).
The P1 domain is released from the polyprotein by 2A
pro. Further processing of the P1 domain into VP0, VP3 and VP1 is by 3CD
pro, followed by the
maturation cleavage of VP0 into VP4 and VP2 by an unknown mechanism. The P2/P3 domains are processed by 3C
pro/3CD
pro to generate different
precursors and mature nonstructural proteins.
doi:10.1371/journal.ppat.1004052.g001
Table 1. Stepwise processing of the P1 capsid protein and
maturation of the PV particle.
P1 precursor protein
I P1* (by associating with Hsp90) processing-competent conformation
II VP0, VP3, VP1 protomer 5S
III (VP0, VP3, VP1)5 pentamer 14S
IV [(VP0, VP3, VP1)5]12 empty capsid (procapsid) 75S
V [(VP0, VP3, VP1)5]12RNA provirion 150S
VI [(VP4, VP2, VP3, VP1)5]12RNA virion 150S
doi:10.1371/journal.ppat.1004052.t001
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that the extent of inhibition did not significantly vary with the
multiplicity of PV1 infection (0.1–10) (data not shown). These
results confirmed our preliminary finding (Figures 2A and 2B) that
GSH is required for the growth of both PV1 and CAV20, two C-
cluster enteroviruses. As shown on Figure 3C, the PV1 virus titer
slowly increased from 4–8 hr post infection in drug-treated cells in
the presence of the drug. In order to determine whether the virus
obtained at 8 hr post infection (Figure 3C) in the presence of BSO
were BSOr variants or just a few wt viruses that escaped the
inhibition by the drug, we tested the growth properties of the
progeny PV1 obtained at 8 hr post infection in both untreated and
BSO-pretreated HeLa cells. We observed that .90% of total
population consisted of BSOr variants (data not shown), an
observation indicating that drug resistant PV1 variants appear
readily when GSH is depleted in the presence of BSO. In contrast,
the virus titer for CAV20-wt in the presence of BSO did not
increase (Figure 3D). This is in agreement with the result in
Figure 3A showing that PV1 can easily become resistant by
acquiring different mutations whereas only one VP3 mutation has
been found in CAV20 that confers it the resistance to BSO. As
mentioned previously, this suggests that CAV20 is much more
sensitive than PV1 to suboptimal levels of GSH such that selection
to resistance is more difficult.
Structural analyses of BSOr mutations within the PV1
capsid
The existence of BSO resistant PV1 or CAV20 variants
indicates that stable 14S particles and mature virus can be
generated even in the absence of GSH. Therefore, it is reasonable
to assume that the BSO resistant mutations have a role in
stabilizing the mature virus and likely also one or more of the
capsid precursors. Therefore we determined the exact location of
the Q178L mutation mutations (Figure 4A) and also of all the
other PV mutations: T254I/VP1, I239V/VP1, T175A/VP3)
(Figure 4B) within the known atomic structure of the capsid [25].
Figure 4A illustrates the PV protomer, shown here as a colored
ribbon, which forms an interface with symmetry related neighbors.
The location of the Q178L mutation is shown with two nearby
protomers highlighted. The other mutations are shown in
Figure 4B, with two protomers highlighted. These mutations
map primarily at protomer/protomer interfaces within the
pentamers, an observation supporting our hypothesis that they
contribute to the formation of a stable capsid even in the absence
of adequate concentrations of GSH. Similarly, the CAV20 Y97H
mutation is predicted to be at or near the Q178L mutation in the
structure of a modeled CAV20 capsid (data not shown). The
Q178L and Y97H mutations are located in the GH loop of VP3
Figure 2. BSO-treatment of HeLa cells inhibits the growth of PV1. (A) HeLa cells were pretreated with 0.4 mM BSO for 48 hr and were
infected with PV1-wt at a moi of 1. The cell lysates were passaged in the presence of the drug until BSOr mutants developed and CPE (cytopathic
effect) was observed. BSOr and wt lysates were used to infect either untreated or drug-treated HeLa cells at a moi of 1 and incubation continued until
CPE. Viral titers were determined by plaque assay, as described in Materials and Methods. Dilution factors used for the plaque assay are given in the
center of the wells. (B) Reversal of BSO-inhibition of PV1 growth by GSH and DTT. BSO-treated HeLa cells were infected with PV1-wt at a moi of 1 in
the presence of 5 mM different reducing agents (GSH, DTT and b-Me) or 5 mM GSSG. Cell lysates harvested at 8 hr post-infection were used to
determine the virus titers by plaque assays (Materials and Methods).
doi:10.1371/journal.ppat.1004052.g002
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Interestingly, the GH loop undergoes major structural rearrange-
ments in the 135S cell entry intermediate of PV suggesting the
possibility that the mutations also play a role during expansion or
uncoating [26].
BSO does not affect CAV20 protein translation or viral
RNA synthesis
To determine the stage of the viral life cycle at which adequate
GSH concentrations are required for virus proliferation, we
labeled the viral proteins with S
35 trans-label in CAV20-wt
infected HeLa cells that were untreated or pretreated with BSO,
and analyzed
35S trans-labeled viral proteins by SDS-PAGE. BSO
had no effect on the translation and processing of the CAV20
polyprotein. Similar to previously reported results [3] no
maturation cleavage of CAV20 VP0 to VP2 and VP4 could be
observed in cells depleted of GSH (Figure 5A, compare lanes 1
and 2), an observation indicating that no infectious particles were
formed. In contrast the CAV20-BSOr variant produced similar
levels of VP2 in the absence or presence of the drug (Figure 5A,
compare lanes 3 and 4). We conclude that BSO treatment of HeLa
cells has no apparent effect on CAV20 protein synthesis and
processing.
The effect of GSH-depletion on viral RNA synthesis was
examined with a CAV20-FLuc replicon in which the capsid
domain of CAV20 was replaced with the FLuc coding sequence
(Figure 5B). BSO-treated or untreated cells were transfected with
RNA transcripts of the CAV20-FLuc replicon both in the absence
or presence of guanidine hydrochloride (GnHCl), a potent
inhibitor of RNA replication [27]. The luciferase signal in the
presence of GnHCl, measures the level of translation of the
transfected replicon, which in BSO treated and untreated cells,
was at normal levels. RNA replication, on the other hand, was
evaluated by measuring luciferase activity in the absence of
GnHCl. Since the luciferase activity, in the absence of GnHCl,
was comparable in BSO-treated and untreated cell cultures
(Figure 5B) we conclude that GSH depletion and BSO have no
inhibitory effect on RNA replication.
BSO inhibits the morphogenesis of CAV20
To test the effect of GSH-depletion on encapsidation we
performed trans-encapsidation assays [17]. Specifically, we mea-
sured the ability of BSOr viruses to trans-encapsidate a CAV20
FLuc replicon. Only those replicons that have been encapsidated
during the transfection step by the capsid of the superinfecting
BSOr virus are expected to produce a Luc signal during passage
Figure 3. BSO resistant PV1 and CAV20 variants and their growth curves in HeLa cells. (A) Identification of BSO resistant mutations in the
capsid of PV1 and CAV20. BSOr mutants of PV1 and CAV20 were plaque purified and after RT/PCR of the viral RNAs the cDNAs were sequenced in the
capsid domain (Materials and Methods). The loci of the mutations in the capsid domain (enlarged) are illustrated. Also included are mutations in the
capsid of PV type 1 Sabin, also a BSOr mutant. The residue or residues responsible for the BSOr phenotype of PV type 1 Sabin has not yet been
identified. (B) The growth of PV type 1 Sabin is not inhibited by BSO. PV type 1 Sabin was grown in the absence or presence of BSO and the virus
titers at 8 hr post infection were determined by plaque assay (Materials and Methods). (C) Untreated and BSO-pretreated cells were infected with
PV1-wt or PV1-BSOr (VP3 Q178L) at a moi of 10. Cultures of infected cells were harvested a 0 hr, 2 hr, 4 hr, and 8 hr post-infection. Virus titers were
determined by plaque assays (Materials and Methods). (D) Untreated and BSO-pretreated cells were infected with CAV20-wt or CAV20-BSOr (VP3
Y97H) at a moi of 1. Cultures of infected cells were harvested at 0 hr, 2 hr, 4 hr, and 8 hr post-infection. Virus titers were determined by plaque assays
(Materials and Methods).
doi:10.1371/journal.ppat.1004052.g003
Figure 4. BSOr mutations are located at the interface between protomers. The poliovirus protomer, shown here as a colored ribbon with
VP1 in blue, VP2 in yellow and VP3 in red, forms an interface with symmetry related neighbors, one of which is shown as a mesh with the same color
scheme. Three remaining symmetry copies are shown in grey to make up the pentameric arrangement around the 5-fold axis. The locations of the
mutations are shown as colored spheres and are predominantly found at the interface between protomers. (A) VP3 Q178L mutation alone; (B) All
BSOr PV mutations. Colors: VP3 Q178L-purple; VP1 D219N-Orange; VP3 T175A-Green; VP1 I239V-Pink; VP1 254I-Cyan. Molecular graphics and analyses
were performed with the UCSF Chimera package and PyMOL Molecular Graphics System, Version 1.5.0.4 Schrodinger, LLC. Chimera is developed by
the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS 9P41GM103311)
[26,43].
doi:10.1371/journal.ppat.1004052.g004
Glutathione & Capsid Interaction in Morphogenesis
PLOS Pathogens | www.plospathogens.org 6 April 2014 | Volume 10 | Issue 4 | e1004052on fresh HeLa cells. HeLa cells were treated with BSO before
transfection with transcript RNAs of a CAV20 FLuc replicon
(Figure 5C) and incubated in the presence of the drug. Six hours
post transfection the cells were superinfected with either CAV20-
wt or CAV20-BSOr virus, both in the absence and presence of
GnHCl. After 6 hr the cells were lysed and an aliquot was used to
measure luciferase activity. Luciferase activity from transfection (-
GnHCl), which measures RNA replication, was comparable in the
cell lysates co-infected with CAV20-wt or CAV20-BSOr viruses
(Figure 5C), confirming our preliminary finding that GSH-
depletion has no inhibitory effect on RNA replication
(Figure 5B). To measure encapsidation, an aliquot of the cell
lysate was used to infect fresh HeLa cells and, again, luciferase
activity was measured at 6 hr post infection. Those replicon-
transfected cells that were superinfected with wt virus produced
only background levels of Luc signal indicating a lack of trans-
encapsidation by the wt capsid. In contrast, high luciferase activity
was detected when superinfection was done with the BSOr virus,
indicating that the capsid derived from the BSOr virus was able to
transencapsidate the replicon. These results indicate that BSO-
induced inhibition of viral growth functions at the level of
morphogenesis.
Binding between GSH and capsid proteins is essential for
virus production
The presence of mutations in VP3 and VP1 in the BSOr
variants (Figure 3A) suggested the possibility that GSH directly
interacts with the wt capsid precursors or virus particles in infected
cells. To examine this possibility, we did GSH-pull down assays
using
35S-labeled lysates of untreated or BSO-treated HeLa cells
that have been infected with wt or BSOr PV1 and CAV20 viruses
(Figure 6A and 6B). The left panel of Figure 6A shows labeled PV1
viral proteins of the input lysates separated by SDS-PAGE
(Figure 6A, lanes 1–4). When the lysates were applied to GSH-
Sepharose beads and the bound material was analyzed again by
SDS-PAGE (Figure 6A, right panel), the pull down mixtures from
Figure 5. The effect of BSO on CAV20 protein translation, RNA replication and transencapsidation. (A) In vivo
35S labeling of CAV20-wt
and CAV20-BSOr viral proteins in the absence and presence of BSO in HeLa H1 cells. Viral proteins were separated on SDS-polyacrylamide gels
(12.5%), as described in Materials and Methods. (B) The genome structure of the CAV20 FLuc replicon used in the experiment is shown above. The
FLuc coding sequence was used to replace the P1 domain of the polyprotein. RNA transcripts of the replicon were transfected into untreated or BSO-
treated HeLa H1 cells either in the absence or presence of GnHCl (2 mM). Luciferase activity was measured at 9 hr post transfection. (C) CAV20 FLuc
replicon RNA transcript was transfected into BSO-treated HeLa H1 cells either in the absence or presence of GnHCl. At 1 hr post-transfection the cells
were superinfected either with wt or with CAV20-BSOr (VP3 Y97H) at a moi of 0.5. The cells were lysed at 6 hr post-infection and were then used to
re-infect fresh HeLa H1 cells in the absence or presence of GnHCl.
doi:10.1371/journal.ppat.1004052.g005
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resolved into VP0, VP1, VP2 and VP3 (Figure 6A lanes 5 and 7).
VP4, the smallest capsid protein, would not be visible under the
conditions of the gel. The observation that both VP2 and VP0
were present in the mixture indicated that both mature virus and
one or more capsid intermediate interacted with GSH. In BSO-
treated cells, VP2 was not detectable in the lysates of cells made
from infection with the PV1-wt virus (Figure 6A, left panel lane 2).
This indicates that very little, if any, mature virus was formed
under these experimental conditions because no VP0 was cleaved
to VP2 and VP4. Moreover, no capsid proteins were present in the
pull down of cell lysates from BSO-treated cells infected with PV1-
wt virus (Figure 6A, lane 6). These results suggested either that no
normal capsid intermediates were made or that these structures
lost their ability to bind to GSH. In the presence of BSO, the PV1-
BSOr variant yielded all viral capsid proteins in the GSH-pull
down (Figure 6A, lane 8). This result suggests that capsid proteins
of the BSOr variants, regardless of the absence of adequate
amount of GSH, possess the correct conformation for the binding
of GSH. Meanwhile, we observed that the viral proteins of
CAV20-wt and CAV20-BSOr virus (Figure 6B, lanes 1–4) share a
similar binding pattern to GSH (Figure 6B, lanes 5–8) as their PV1
counterparts, indicating that the interaction of GSH to capsid
proteins is a general phenomena within C-cluster enteroviruses.
The fact that the loss of binding of capsid proteins to GSH in PV1-
wt leads to its failure to generate viable virus strongly suggests that
the interaction of capsid proteins with GSH is important for virus
production.
BSO treatment of HeLa cells reduces the level of 14S
pentamers and alters the mobility and stability of 150S
particles
With the aim of determining which step of particle assembly is
inhibited by BSO we applied
35S-labelled PV1-wt infected HeLa
cell lysates, made in BSO treated or untreated cells, to sucrose
gradients to separate the 5S, 14S, 75S and 150S fractions
(Figures 7A and 7B). It should be noted that the 150S fraction
usually contains both provirions and mature virions. Lysates
prepared from infected but BSO-untreated HeLa cells yielded
gradients with distinct peaks of all intermediate structures and
virus particles [28]. In contrast, the gradients made with lysates of
BSO-treated cells exhibited normal 5S and 75S peaks but
strikingly lower amounts of the 14S peak (Figure 7A). There are
several possible explanations for the reduced amounts of 14S
material visible on the gradient. First, there might be fewer
pentamers made under conditions of insufficient GSH. In this case
the production of subsequent capsid precursors, 75S and 150S,
would have been decreased accordingly. However, the sucrose
gradient profiles clearly showed that the peaks of 75S and 150S
particles, in the presence of BSO, are comparable to their
counterparts generated in the absence of the drug. Alternatively,
the 14S pentamer particles are produced in normal amounts but
are unstable in the absence of sufficient amounts of GSH. This
explanation supports our hypothesis that the role of GSH during
morphogenesis is to stabilize the 14S pentamers but it does not
explain the seemingly normal production of 75S particles. As will
be seen below in the GSH-pull down assay (Figure 7E), the
properties of 75S particles produced in GSH-depleted HeLa cells
are indeed different from those made in untreated HeLa cells.
We observed reproducibly in experiments with GSH-depleted
cells a 150S peak, which migrated faster than the 150S peak
obtained in untreated lysates (Figure 7B). As far as the shift in
mobility of the 150S particle is concerned, these results suggest a
malformation of the 150S particle, likely producing noninfectious
virus particles. To test this hypothesis, we compared the virus titers
in the 150S peaks, derived from lysates made in untreated or BSO-
treated HeLa cells. Indeed, the infectious virus titer in the +BSO
150S peak was only about 3% of the plaque forming units
generated under normal growth conditions (2BSO) (Figure 7C).
The combined results of the sucrose gradients, especially the
abnormal profiles of the 14S and 150S particles, suggest that 14S
pentamers formed under GSH-depletion might have a different
conformation that renders them unstable and unable to form
normal 150S, even though they are still able to associate with the
viral RNA.
GSH interacts with capsid precursors
In Figure 6A we showed that VP0 was present in the GSH-pull
down mixture indicating that one or more capsid intermediates
interacted with GSH. To determine which capsid precursor binds
to GSH we individually pooled three fractions of each peak,
containing the highest levels of
35S label (Figures 7A and 7B), and
subjected aliquots to GSH-pull down assays. The viral capsid
proteins present before (input) and after pull down with GSH (pull
Figure 6. GSH directly interacts with capsid proteins of both PV1 and CAV20. (A) GSH-pull down assay of PV1-infected lysates. HeLa cells,
untreated or BSO-treated, were infected with PV1-wt or PV1-BSOr (VP3 Q178L). (B) GSH-pull down assay of CAV20-infected lysates. HeLa cells,
untreated or BSO-treated, were infected with CAV20-wt or CAV20-BSOr. The viral proteins were labeled with
35S-Translabel from 4 to 5 hr post-
infection and the cells were harvested. The viral proteins in an aliquot of the lysates were analysed on SDS-polyacrylamide (11.5%) gels (lane 1–4).
Samples were loaded onto GSH Sepharose beads and the pulled down material was analyzed by SDS-PAGE (lane 5–8).
doi:10.1371/journal.ppat.1004052.g006
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made from untreated HeLa cells yielded the expected capsid
proteins after GSH-pull down in all peaks except the 5S. This 5S
peak contained primarily unidentified protein bands suggesting
that most of the label in the peak (Figure 7A) is not capsid related
(Figure 7E, lanes 2 and 7). After the pull down of lysates made in
GSH-depleted cells no capsid proteins were detected from the 5S,
14S and 75S peaks and only trace amounts of capsid proteins were
visible in the 150S peak (Figure 7E, lanes 7–10). A comparison of
protein band intensities in the 150S peaks in lane 10 of Figure 7D,
and Figure 7E suggests that these proteins are derived from the
BSOr variants, which represent 3% of the normal virus titer as
shown in Figure 7C. Overall these results suggest that GSH can
bind to capsid intermediates under normal conditions. This
binding might be crucial for morphogenesis because it confers the
14S pentamer a stable conformation that is required for forming
normal 150S particles, which can mature into infectious virions.
GSH binds to mature virus particles
The presence of VP2 in the GSH-pull down mixture suggested
that GSH might also bind to the virion (Figure 6B). To confirm the
interaction of GSH with mature virion particles, CsCl-purified
mature viruses (Figure 7F, lane 1), made in the absence of BSO,
were subjected to GSH-Sepharose pull down assays and the bound
viral proteins were analyzed by SDS-PAGE (Figure 6F). As a
control we also analyzed also empty Sepharose beads, which
yielded no visible bands (Figure 7F, lane 2). The bound proteins in
the purified virus preparation consisted of the expected amounts of
VP1, VP2, and VP3 (Figure 7F, lane 3). It should be noted that the
amount of labeled amino acids (Cys+Met) in VP1 (7) is about one
half of what it is in VP2 (14) or VP3 (17), therefore the VP1 band
in the gel appears significantly lighter than the other two bands. A
trace of uncleaved VP0 in the GSH-pull down suggests the
presence of a small amount of provirion in the virus band. These
results confirm a direct binding between GSH and the mature
virus and possibly also the provirion.
Lysates made from cells infected with PV1-wt, under GSH-
depletion condition, did not yield any virus band in a parallel CsCl
gradient (data not shown). The lack of a band at the expected
location of the gradient indicates that the 150S particles made
under these conditions are unstable and fall apart, probably during
our purification procedure that includes a strong detergent, SDS.
Immunofluorescence cell imaging of BSO-untreated or -
treated HeLa cells infected with wt and BSOr viruses
To confirm that mature virus is not formed in BSO-treated
infected cells, we used immunofluorescence cell imaging. Untreated
or BSO-treated HeLa cells were infected with PV1-wt (moi 10). At
4 hr post infection the cells were probed for the presence of mature
virus [with monoclonal antibody (mcAb) A12] and for 3AB (with
mc3AB), the latter being an essential viral protein component of the
replication complex. In untreated cells (Figure 8A, 2BSO lane),
mature virus and 3AB colocalize at the peri-nuclear region of the
infected cell whereas no mature virus particles were detected under
the conditions of the experiment in drug-treated cells (Figure 8A,
+BSO lane). In a similar experiment with a PV1-BSOr variant
(VP3, Q178L), mature viruses were observed in equal amounts in
untreated or drug-treated cells (Figure 8A, 2/+BSO lanes).
As we mentioned before, the 150S peaks derived from GSH-
depleted lysates (+BSO) were present in about the same amount as
the ones made in untreated cell lysates (Figure 7B). These results
suggested that BSO has no direct effect on the interaction between
capsid precursors and the protein components of the replication
complex. To confirm this observation we again used immunoflu-
orescence cell imaging to examine the localization of VP3 (with
VP3 polyclonal antibody) and of 2C
ATPase (with 2CmcAb) in
infected cells that were either untreated or BSO-treated. A specific
VP3/2C
ATPase interaction has recently been reported by us to be
essential for poliovirus morphogenesis [21,22]. Our results clearly
showed normal colocalization of VP3 and of 2C
ATPase, both in
BSO-treated and untreated cells (Figure 8B). The same results
were obtained when PV1-BSOr (VP3, Q178L) was used instead of
the wt virus (Figure 8B). The successful localization of the capsid
precursors to the replication complex in BSO-treated cells suggest
that the structural (conformational) change in the capsid precursor
due to GSH-depletion does not affect the direct protein-protein
interactions between the VP3-component of capsid precursors and
2C
ATPase on the replication complex.
GSH protects purified poliovirus particles from heat
inactivation in vitro
Early studies with poliovirus have shown that methylthiopyr-
imidine, S7, and GSH can protect the virus from heat inactivation
in vitro [10]. To examine the protective role of GSH during heat
inactivation of PV1, we carried out a series of in vitro experiments
with both PV1-wt and a PV1-BSOr variant (VP3 Q178L). The
viruses, purified on sucrose cushions, were incubated at 48uC for
25 minutes, in the absence or presence of GSH, and the fold
change in titer was examined (Figure 9A). For either PV1-wt or
PV1-BSOr virus, the results are presented as ‘‘fold change’’
relative to the virus titer obtained after heat inactivation in the
absence of GSH, which is taken as ‘‘1’’. During heating the titer of
the wt virus was reduced about 1000-fold while that of the BSOr
changed only 150-fold. When GSH was present during heating,
Figure 7. GSH interacts with encapsidation intermediates and mature virus. (A) Separation of 5S and 14S capsid intermediates on a sucrose
gradient. Untreated and BSO-treated HeLa cells were infected with PV1-wt (moi 10) and metabolically labeled with
35S-Translabel from 4–6 hr post-
infection. Cell lysates were made and were analyzed on a 6–25% sucrose gradient for the separation of 5S and 14S intermediates (Materials and
Methods). Fractions were collected from the top and the radioactivity in each fraction was determined by scintillation counting. (B) Separation of 75S
and 150S particles on a sucrose gradient. Untreated and BSO-treated HeLa cells, infected with PV1-wt (moi 10) were labeled with
35S-Translabel, as
described above, and the cell lysates were analyzed on a 15–30% sucrose gradient for the separation of the 75S and 150S intermediates (Materials
and Methods). Fractions were collected from the top and counted by scintillation counting. (C) Comparison of virus titers of 150S peak fractions
derived from 2BSO and +BSO gradients. 10 ml of 150S fractions, derived from both BSO-treated and –untreated infections, were titered by plaque
assay (Materials and Methods). (D) GSH-pull down assays of capsid intermediates and of virus derived from 2BSO lysates. Three fractions of each of
the 5S, 14S, 75S and 150S peaks were pooled and an aliquot of each was analyzed by SDS-polyacrylamide (11.5%) gel electrophoresis (lanes 1–5).
Only one part of the gel is shown, which contains the major capsid proteins. Lanes 6–10 show the proteins pulled down by GSH beads from the
lysates and from the intermediate peaks. (E) Lanes 1–5 show the input
35S-labeled viral proteins in +BSO lysates and its capsid intermediates. Lanes 6–
10 show proteins pulled down from the lysates or from the capsid intermediate peaks by GSH-Sepharose (Materials and Methods). (F)
35S-labeled
lysates made in the absence of BSO were purified and subjected to CsCl centrifugation (Material & Methods). The virus band (2BSO) containing
mature virions was isolated and an aliquot was applied to GSH Sepharose beads. The pull down sample was analyzed by SDS PAGE. Sepharose 4B
beads were used as control.
doi:10.1371/journal.ppat.1004052.g007
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manner from 0.1 mM to 5 mM. GSH provided stronger
protection to the wt virus than to the BSOr variant. GSSG, the
oxidized form of GSH, was also able to protect the wt or BSOr
viruses from heat-inactivation (Figure 9B) but neither b-ME nor
DTT (5 mM) provided such protection (Figure 9B). These results
suggest that protection from heat inactivation requires a direct
interaction between GSH or GSSG and the virus particles but a
reducing environment is not sufficient. In addition they suggest
that the BSOr mutants are more resistant to heat inactivation than
the wt virus and less dependent on GSH than the wt, likely
because the BSOr capsids are more stable. In combination with
the results in Figure 7F, we conclude that the function of the
interaction between GSH and mature viral particles in vitro is to
stabilize the virions.
Discussion
An effect of intracellular GSH concentration on viral prolifer-
ation is known for several years [3–7,29] but the mechanism of
GSH’s influence on viral metabolism is largely obscure. In most
cases reducing intracellular GSH concentration aids viral prolif-
eration and pathogenesis but Smith and Dawson (2006) reported a
strong inhibition of coxsackievirus B3 (CVB3) proliferation in cells
nearly void of GSH. They made use of a drug, called BSO, that
interferes with GSH biosynthesis [2] and they presented evidence
suggesting that the block was in morphogenesis.
The mechanism of poliovirus morphogenesis is the least
understood step in viral proliferation. Although the basic steps of
PV morphogenesis have been established (Table 1), very little is
known about the details of this process. We have recently studied
steps in morphogenesis of PV1 and CAV20, which are C-cluster
human enteroviruses, and have suggested that genome encapsida-
tion occurs without the involvement of an RNA packaging signal;
instead encapsidation specificity relies on the interaction between
2C
ATPase (in the replication complex) and capsid proteins VP3 and
VP1 [21,22].
In an effort to extend our understanding of the mechanism of
enterovirus morphogenesis, we have undertaken a study of the role
of GSH in enterovirus proliferation with the use of BSO, an
inhibitor of GSH biosynthesis. Depletion of GSH with BSO is slow
(48 hr) but highly efficient [3]. Notably, the nearly complete
removal of GSH had no effect on CAV20 translation or processing
and on genome replication. The same was found for PV1 infected
GSH-depleted HeLa cells (data not shown). Yet the production of
infectious PV1 and CAV20 virions was inhibited .100 fold.
We then searched for and found PV1 and CAV20 mutants
(referred to as BSOr mutants) that replicated to high titers in
GSH-depleted cells. Notably, the mutations in all BSOr variants
mapped to capsid protein VP1 and VP3 (Figure 3A), and none to
2C
ATPase. Moreover, nearly all mutations mapped to interfaces of
protomers within the pentamers (Figure 4). Failure to score escape
mutants in 2C
ATPase was at first disappointing but it suggested that
the interaction between 2C
ATPase and VP3/VP1 is not affected by
GSH. The PV type 1 Sabin, which is BSO-resistant, contains
mutations in all of the capsid proteins but it is not known which
one is responsible for the BSOr phenotype. Interestingly, the
temperature sensitive phenotype of PV type 1 Sabin is due to a
defect in the assembly of 14S particles and mature virions [30].
A key observation in this study was that the mature wt virus and
capsid precursors of both PV1 and CAV20 were all pulled down
by GSH-Sepharose beads (Figure 6). This indicated a direct
interaction of the viral structural components and of the virion
with GSH. GSH depletion with BSO eliminated those interactions
(Figure 6). However, virus particles derived from BSOr variants,
grown in GSH-depleted cells in the presence of BSO, were fully
capable of interacting with GSH (Figure 6). All of these data
strongly indicate that the interaction of GSH with capsid proteins
is important for producing infectious virus particles.
At what stage does GSH play its role in C-cluster enterovirus
morphogenesis? We have infected normal and GSH-depleted
HeLa cells with PV1-wt and PV1-BSOr and analyzed progeny
virus and packaging intermediates by sucrose gradients (Figure 7).
Infection of untreated cells produced the well-known patterns of
5S, 14S, 75S and 150S peaks, a signature of normal morphogen-
esis intermediates. In BSO-treated cells, however, an adequate
accumulation of 14S pentamer was reproducibly missing. More-
over, in the 150S region, some material sedimenting slightly faster
than wt 150S virions accumulated. This material contained very
little infectivity and it did not survive purification and analysis in
CsCl gradients.
These data suggested that GSH has very important functions in
morphogenesis by promoting the formation of stable capsid
precursors and of the mature virus. In particular, GSH appears to
be required for the accumulation of 14S pentamers. There are two
possible explanations for the reduced amounts of 14S material
visible on the gradient. First, without GSH the 14S pentamers are
unstable, which, however, still associate with RNA and form non-
infectious particles that sediment faster than virions. Alternatively,
the unstable pentamers are depleted from the lysate by being
rapidly incorporated into 75S empty capsids, which normally are
the transient storage forms of pentamers that spontaneously
assemble and disassemble [14,17–20]. However, in the presence of
the drug, the inability of 75S particles to bind GSH indicates some
type of abnormality in their capsid structure or conformation that
makes them unable to dissociate back to 14S.
Overall, the failure of these capsid precursors to bind to GSH,
their mobility shift in sucrose gradients, and their instability in
CsCl gradients, clearly indicate that GSH is required for
maintaining their structure or conformation, particularly that of
the 14S pentamers. Early studies on PV capsid assembly suggested
the existence of an ‘‘activated’’ 14S particle whose formation was
dependent on a ‘‘morphopoietic factor’’ present in virus-infected
cell extracts and to a lesser extent in uninfected HeLa extracts
[31,32]. Whether or not this factor was GSH remains to be
determined.
It is interesting to note, in the context of 14S particle assembly,
that a lack of myristolylation of VP0 also leads to a reduction or
block in the assembly of protomers to pentamers [33–35]. It was
suggested that the myristate moieties, clustered near the contact
Figure 8. Immunofluorescence cell imaging of PV1-infected HeLa cells in the presence and absence of BSO. (A) HeLa cells were
infected with PV1-wt or PV1-BSOr (VP3 Q178L) at a moi of 10 at 37uC. After 4 hours incubation, the infected cells were probed for mature virus with
A12 primary antibody (anti-PV human serum), which binds specifically to mature virus and provirions (Nihal Altan Bonnet, unpublished results), and
Alexfluor 488-conjugated secondary antibody (green color). The localization of 3AB, a member of the replication complex, was determined in the
same cell using 3AB mouse monoclonal antibody and Alexfluor 555-conjugated secondary antibody (red color). The scale is 5 mm. (B) Infected cells
were probed for capsid precursors using VP3 polyclonal antibody and Alexfluor 488-conjugated secondary antibody (green color). The localization of
2C
ATPase, another nonstructural protein on the replication complex, was determined in the same cell using 2C mouse monoclonal antibody and
Alexfluor 555-conjugated secondary antibody (red color).
doi:10.1371/journal.ppat.1004052.g008
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involved in stabilizing the pentamers. Whether there is any type of
interaction between the myristate group of VP0/VP4 and GSH in
stabilizing these precusors is not known.
The BSOr variants appear to require no or little GSH for capsid
stability, an observation indicating that the capsid mutations
restore the proper protomer/protomer interactions that are
required for the formation of stable 14S pentamers and,
subsequently, of mature virus. Nevertheless, the BSOr variants
retain their ability to bind GSH as evidenced by pull-down
experiments. There are two possible explanations of these findings.
First, that the GSH binding site(s) on the structure of the capsid is
completely different than the locations of the BSO resistant
mutations. Therefore the ability to bind GSH is not related in
anyway to a requirement (or a lack of requirement) of GSH for
growth. The BSOr mutant might not need to bind GSH for
growth because its 14S particle and capsid are already stable
enough for normal morphogenesis. Second, compared with the
capsid precursors of the wt virus, the BSOr capsid precursors
might have a higher affinity for GSH enabling the BSOr mutants
Figure 9. GSH protects PV1-wt and PV1-BSOr from heat inactivation. (A) Protection from heat inactivation of PV1-wt or PV1-BSOr by GSH.
Purified PV1-wt or PV1-BSOr (VP3, Q178L) 3610
9 PFU was incubated in vitro in PBS either in the absence or presence of various amounts of GSH for
25 min at 48uC. The amount of virus remaining after the incubation was determined by plaque assays. The virus titers obtained after heating without
GSH for both viruses were taken as ‘‘1’’. (B) Protection from heat inactivation of PV1-wt or PV1-BSOr by reducing agents or GSSG. PV1-wt or PV1-BSOr
3610
9 PFU were incubated in PBS either in the absence or presence of various reducing agents (5 mM) or of GSSG (5 mM) (Materials and Methods).
The virus titer obtained after heating without GSH for both viruses were taken as ‘‘1’’.
doi:10.1371/journal.ppat.1004052.g009
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GSH.
Our previous genetic and biochemical studies have established
that the 2C
ATPase protein, a viral polypeptide central in genome
replication, interacts with capsid proteins, particularly VP3, and
that this interaction is essential for morphogenesis [21,22]. At the
height of poliovirus proliferation, both poliovirus genome replica-
tion and morphogenesis occur on peri-nuclear membranes of
infected cells. Immunofluorescence cell imaging experiments
shown here clearly indicate that in GSH-depleted cells, virions
are not formed at any site in the infected cell, and particularly not
on peri-nuclear membranes. Normal replication is seen, however,
in cells infected with PV1-BSOr variants regardless of whether the
cells were GSH-depleted or not (Figure 8A). In contrast, capsid
protein VP3 and polypeptide 2C
ATPase that co-localize in the peri-
nuclear membranes during ordinary infection, are still found
together in normal and GSH-depleted cells, irrespective of
whether the cells were infected with PV1-wt or BSOr
(Figure 8B). Therefore, whatever influence GSH depletion has
on the structures of the capsid related particles this does not
prevent normal association of 2C
ATPase/replication complex with
the VP3 polypeptide contained in these particles. This is consistent
with the observation that capsid proteins obtained from BSO-
treated cells can still associate with RNA to form 150S, albeit
unable to produce mature virion.
Does the depletion of GSH induce an alternative, hostile
condition (other than lack of GSH) in the host cell that would
interfere with capsid assembly, such as turnover of host factors
essential for morphogenesis? We cannot rigorously exclude such
scenario. However, the inhibitory state of BSO-treated cells can be
reversed by adding GSH to the cell culture 2 hr after infection and
harvesting for progeny virus after a single growth cycle. Although
replication cannot be restored to wt levels under the conditions of
the experiment, synthesis of progeny to titers of 7 logs makes it
unlikely that essential host factors were synthesized during the
short time. Unexpectedly, DTT, a reducing agent normally not
present in infected cells, was also able to partially reverse the effect
of BSO-treatment. We assume that the effect of DTT is indirect,
for example it might function by reducing GSSG, which
accumulated in the cell during GSH starvation, to GSH. It should
be noted that DTT does not reverse the effect of GSH-depletion
during CVB3 infection of cells [3].
Heating of poliovirus particles causes extensive alterations to
their physical and biological properties [36–38]. Heat-inactivated
virus particles lose VP4 and are not able to adsorb to host cells
thereby losing infectivity and their antigenic properties are
changed [36]. Early studies on the stability of PV have shown
that in vitro heat inactivation of the virus can be prevented by the
addition of thiol compounds such as GSH or S7 (ethyl-2-
methylthio-4-methyl-5-pyrimidine carboxylate) [10]. Our current
experiments indicate that both GSH and GSSG are able to protect
PV1-wt from heat-inactivation but DTT or b-ME cannot. These
results suggest that the reducing ability of GSH is not important in
preventing heat-inactivation but that direct binding increases heat
stability. Compared to the wt virus, the BSOr variant is much
more resistant to heat inactivation and exhibits less dependence on
GSH for protection from heat inactivation. Therefore, it is likely
that the BSOr variants are particles of increased physical stability
formed by bypassing the inadequate GSH supply.
Based on our results we propose the following model for the role
of GSH in morphogenesis (Figure 10). Under normal growth
conditions GSH binds to and stabilizes the 14S particles and
enhances their assembly into the provirion/virion after association
with RNA. In the presence of BSO the GSH concentration in the
cell is too low for the stabilization of the pentamers, which may fall
apart. In contrast, PV1-BSOr mutants, whose capsid proteins may
have higheraffinitytoGSH,donothavedifficultyassemblingunder
low GSH concentrations and form more stable 14S pentamers.
Materials and Methods
Materials
L-buthionine-S,R-sulfoximine (BSO), Glutathione (GSH), oxi-
dized Glutathione (GSSG) and DL-Dithiothreitol (DTT) were
purchased from Sigma-Aldrich.
35S-Translabel (1000 C/mmol),
containing labeled methionine and cysteine, and Actinomycin D
were products of MP Biochemicals. Guanidine HCl, GSH
Sepharose 4B, and Sepharose 4B, were purchased from Qiagen,
BioWorld, and GE, respectively.
Plasmids
pT7PV1(M) and pT7CAV20 contain the full-length infectious
cDNA of PV1(M) and CAV20, respectively [39,40]. PV(Sab)
consisting of the cDNA of full-length infectious PV type 1 Sabin
[24] was a gift of Dr. Akio Nomoto. The CAV20-FLuc plasmid was
generated by replacing the P1 coding region of CAV20 with the
fireflyluciferase gene(FLuc).A 2A
pro cleavage site is inserted between
coding sequence of FLuc and the P2 nonstructural polyprotein.
Cells and viruses
HeLa H1 or HeLa R19 cells were maintained in Dubecco’s
modified Eagle’s medium (DMEM) (Life Technology) supple-
mented with 8% bovine calf serum (Thermo Scientific), 100 units/
ml of penicillin-streptomycin (Life Technology). Poliovirus type 1
(Mahoney) PV1-wt and coxsackievirus A20 (CAV20), two C-
cluster enteroviruses, were derived from their respective cDNAs,
pT7PVM and pT7CAV20. PV type 1 Sabin virus was derived
from the PV(Sab) cDNA.
Plaque assays
Plaque assays were performed in HeLa R19 cells using 0.6%
tragacanth gum [41]. The plates were incubated for 48 hr at 37uC
and were stained with 1% crystal violet.
Isolation of PV1 and CAV20 BSO resistant mutants
BSO-starved HeLa cells were infected with PV1-wt at a moi
(multiplicity of infection) of 0.01 and incubated in the presence of
BSO for 24 hr at which time partial CPE was observed. The
infected cells were lysed and an aliquot of the lysate was passaged on
fresh BSO-treated cells. PV1-BSOr mutants evolved rapidly,
already during the first passages on BSO-treated HeLa cells. The
PV1-BSOr mutants were plaque purified and the RNAs were
subjected to RT-PCR and sequence analysis. Thirteen independent
plaques were sequenced in the P1 domain and found to contain
three types ofmutations (Fig.3A).FortheisolationofCAV20-BSOr
mutants BSO-treated HeLa cells were infected with CAV20 at a
moi of 1–2 and incubated in the presence of BSO. After 24 hr
incubation the infected cells were lysed and an aliquot was used to
infect fresh BSO-treated cells. CAV20-BSOr appeared after 3
passages on HeLa cells. The CAV20-BSOr mutants were plaque
purified and the RNAs were subjected to RT-PCR and sequence
analysis. The entire RNA genome of four independent plaques was
sequenced and only one type of mutation was observed (Figure 3A).
RT-PCR and sequencing analysis of viral RNA
Plaque purified viruses were used to infect HeLa cells and at
7 hr postinfection, total cytoplasmic RNAs were extracted with
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and amplified into cDNA using the Titan one tube RT-PCR
system (Roche). The cDNA products were sequenced using the Big
Dye Terminator sequencing Kit (ABI).
Growth curves of PV1-wt, PV1-BSOr, CAV20, CAV20-BSOr
viruses
HeLa cells, untreated or pretreated with 0.4 mM BSO for 48 to
72 hr, were infected with PV1-wt or PV1-BSOr, CAV20, CAV20-
BSOr or PV type 1 Sabin virus at a moi of 10. Incubation was
continued in the presence of 0.4 mM BSO. Cultures were
harvested at 0, 2, 4, 8 hr post-infection and the virus titers were
determined by plaque assays. The Sabin1 culture was harvested at
8 hr post-infection.
In vitro translation
In vitro translations were performed with HeLa cell-free extracts
at 34uC, as described previously [41]. The viral proteins were
analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
containing 11% or 12.5% acrylamide.
35S-Labeling of CAV20 viral proteins in vivo
HeLa H1 cells were either untreated or pretreated with 0.4 mM
BSO for 48 to 72 hr before infection with CAV20 at a moi of 10.
Incubation was continued in the presence of 0.4 mM BSO. The
viral proteins were labeled with
35S-Translabel (a mixture of
methionine and cycteine) 4–6 hr post-infection and were analyzed
by SDS-PAGE.
Viral RNA synthesis
HeLa H1 cells were pretreated with BSO for 48 to 72 hr and
transfected with the CAV20-Fluc replicon RNA in the presence of
0.4 mM BSO. Incubation was continued in the presence of
0.4 mM BSO. When indicated, 2 mM GnHCl (guanidine
hydrochloride) was added at the time of transfection. RNA
replication was measured at 9–12 hr post-transfection by measur-
ing the luciferase signal (Promega) in an Optocomp I luminometer
(MGM).
Transencapsidation assay of CAV20-Fluc replicon RNA
Transcript RNA of the CAV20 replicon was transfected into
BSO-pretreated HeLa H1 cells and incubated in the presence of
0.4 mM BSO. At 1 hr post-transfection, the cells were superin-
fected with either CAV20-wt or CAV20-BSOr at a moi of 0.5 and
incubation was continued in the presence of 0.4 mM BSO. Cells
were lysed at 6 hr postinfection by freezing and thawing and the
lysates were used to re-infect fresh HeLa cells. Luciferase signal
was determined at 6 hr post-infection.
Sedimentation analysis of virus capsid intermediates by
sucrose gradient fractionation
Briefly, untreated or BSO-pretreated HeLa cells in 15 cm dishes
were infected with PV1-wt at a moi of 10. 50 ml Actinomycin D
(1 mg/ml) was added 1 hr after infection to the cultures. At 4 hr
postinfection, 200 mCi of
35S-Translabel was added and incuba-
tion was continued for 2 hr. The labeled cells were washed and
harvested in TNM buffer (10 mM Tris pH 7.5, 10 mM NaCl,
Figure 10. Model for the role of GSH in the morphogenesis of C-cluster enteroviruses. Capsid precursor P1, in a complex with Hsp90, is
processed by 3CD
pro yielding mature viral proteins VP0, VP1 and VP3, which spontaneously form 5S protomer. Under normal growth conditions, with
ample supply of GSH, 5 protomers assemble into a pentamer (14S). The pentamers then either form an empty capsid or condense around the
progeny RNA and form a provirion. The mature virus is derived from the provirion after the cleavage of VP0 to VP2 and VP4. When GSH levels are low,
due to the presence of BSO, the pentamer is unstable. However, these unstable 14S pentamers can associate with RNA and form provirion-like
particles, which can’t mature into an infectious virus. The capsid of the BSOr mutants is more stable than that of the wt virus and requires much lower
levels of GSH for the assembly of the precursors and the mature virus.
doi:10.1371/journal.ppat.1004052.g010
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natants were applied to a 6 to 25% or to a 15 to 30% sucrose
gradient. The 6 to 25% gradients were centrifuged at 39,000 rpm
for 16 hr in a SW41 rotor (Beckman) for the separation of the 5S/
14S intermediates. The 15 to 30% sucrose gradients were
centrifuged for 2.5 hr for the separation of 75S/150S intermedi-
ates. For each gradient, about 30 fractions (400 ml) were collected
from the top and the radioactivity was quantified by liquid
scintillation counting (Perkin Elmer).
Purification of
35S-labeled virus by CsCl centrifugation
Eight 15 cm plates of HeLa R19 cells, each containing 4610
7
cells, were starved for methionine and cysteine in DME (-Met, -
Cys). The cells were infected with PV1-wt at a moi of 50 and after
one hour 50 mg/ml Actinomycin D was added to each plate. At
4 hr post infection 200 mCi of
35S-Translabel was added to each
plate and the incubation was continued for 2 hr more. The cells
were harvested, washed with DME, and lysed by freezing &
thawing. The cell debris was removed by centrifugation, and to the
supernatant, SDS and EDTA were added to a final concentration
of 1% and 4 mM, respectively. The mixtures were centrifuged for
3.5 hr at 30,000 RPM (TY 50.2 Ti, Beckman) at 21uC. The pellet
was resuspended in 0.4 ml of PBS and mixed with 2.2 g CsCl in
4.5 ml PBS. The mixture was centrifuged at 40,000 RPM for
18 hr in a Beckman SW50.1 rotor at 21uC. An identical sample,
which was made from cells treated with BSO, was run in a parallel
tube. The virus band isolated from the 2BSO gradient was
dialyzed against PBS.
GSH-pull down assay
100 ml of Glutathione Sepharose 4B beads (GE Health Life
Science) were washed 3 times with 500 ml of TNM buffer
containing protease inhibitor cocktail tablets (Roche) before
incubation with the protein samples. After overnight incubation
with viral proteins at 4uC, the Glutathione Sepharose 4B beads
were washed with 500 ml TNM buffer 6 times. The protein
samples bound to the beads were analyzed by SDS-PAGE. In all
GSH-pull down assays, Sepharose 4B beads were used as control.
GSH-pull down assay of in vivo
35S labeled viral proteins
250 mlo fin vivo
35S labeled virus infected cell lysate (about one
forth of total lysate harvested from 35 mm dish) was mixed with
100 ml of GSH-sepharose 4B beads or Sepharose 4B Beads and
subjected to a GSH-pull down assay.
GSH-pull down assay of mature virus
CsCl purified virus 50 ml (1/15
th of the band) was incubated
either with Sepharose B beads or GSH Sepharose beads and
subjected to a GSH-pull down assay.
GSH-pulldown assay of capsid intermediates
Aliquots of the 5S, 14S, 75S and 150S peaks, separated by
sucrose gradient centrifugation, were analyzed by SDS PAGE.
Approximately equal amounts of each peak, estimated by the
quantity of label in the VP3 bands on the gel, were used for the
GSH-pull down assays.
Immunofluorescence cell imaging
HeLa cells, untreated or BSO treated, were infected with wt or
BSOr virus at a moi of 10 and were incubated for 4 hr at 37uC, in
the absence or presence of 0.4 mM BSO, respectively. The
infected cells were probed for mature virus with A12 primary
antibody, which binds specifically to mature virus, and Alexfluor
488-conjugated secondary antibody. A12, kindly provided to us by
Nihal Altan-Bonnet, is a monoclonal antibody originally isolated
and characterized by Chen et al. [42]. Capsid precursors were
probed by polyclonal VP3 antibody. The localizations of 3AB and
2C
ATPase, members of the replication complex, were determined
in the same cell using 3AB and 2C
ATPase mouse monoclonal
antibodies (isolated in our laboratory) and Alexfluor 555-conju-
gated secondary antibody. The scale is 5 mm.
PV heat-inactivation assay
3610
9 PFU of PV1-wt or BSOr viruses were diluted in 200 ml
PBS and were incubated at 48uC for 25 min in the absence or
presence of GSH and other chemical reagents. Samples were
cooled in ice and the virus titers were determined by plaque assay.
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